Drybench Patent.
LINACLOTIDE, NDA 202811
The patents and exclusivities FDA's Orange Book lists for NDA 202811 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 12 Jun 2026 to 16 Feb 2034, each by its own rule; no one date stands for this product.
- Earliest listed date
- 12 Jun 2026I-921 exclusivityRule R3 · Products 001, 003 · exclusivity.txt lines 294, 297
- Latest listed date
- 16 Feb 2034US 9,708,371 with pediatric exclusivity, as listedRule R2 · Products 001, 002, 003 · patent.txt lines 3,343, 3,357, 3,373
- Latest substance patent
- 28 Feb 2027US 7,304,036 with pediatric exclusivity, as listedRule R2 · Products 001, 002, 003 · patent.txt lines 3,331, 3,347, 3,365
- Latest listed patent
- 16 Feb 2034US 9,708,371 with pediatric exclusivity, as listedRule R2 · Products 001, 002, 003 · patent.txt lines 3,343, 3,357, 3,373
- Latest exclusivity
- 21 May 2029NPP exclusivityRule R3 · Product 003 · exclusivity.txt line 298
27 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 202811, as listed. The sections below name products by these numbers.
Product 001 · LINZESS
- Dosage form; route
- CAPSULE;ORAL
- Strength
- 145MCG
- Approval date as listed
- 30 Aug 2012
- Type as listed
- RX
- Applicant as listed
- ABBVIE INC
Product 002 · LINZESS
- Dosage form; route
- CAPSULE;ORAL
- Strength
- 290MCG
- Approval date as listed
- 30 Aug 2012
- Type as listed
- RX
- Applicant as listed
- ABBVIE INC
Product 003 · LINZESS
- Dosage form; route
- CAPSULE;ORAL
- Strength
- 72MCG
- Approval date as listed
- 25 Jan 2017
- Type as listed
- RX
- Applicant as listed
- ABBVIE INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
30 entries from 46 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 7,304,036, substance and product and use patent
patent.txt line 3,334- Expiry as listed
- 30 Aug 2026
- Rule
- R1
- Flags
- substance · product · use code U-4345
- Product numbers
- 001
US 7,304,036, substance and product and use patent
patent.txt lines 3,332, 3,348- Expiry as listed
- 30 Aug 2026
- Rule
- R1
- Flags
- substance · product · use code U-1278
- Product numbers
- 001, 002
US 7,304,036, substance and product and use patent
patent.txt lines 3,333, 3,349, 3,366- Expiry as listed
- 30 Aug 2026
- Rule
- R1
- Flags
- substance · product · use code U-1516
- Product numbers
- 001, 002, 003
US 7,304,036, substance and product and use patent
patent.txt line 3,367- Expiry as listed
- 30 Aug 2026
- Rule
- R1
- Flags
- substance · product · use code U-3644
- Product numbers
- 003
US 7,304,036, substance and product and use patent
patent.txt line 3,368- Expiry as listed
- 30 Aug 2026
- Rule
- R1
- Flags
- substance · product · use code U-4566
- Product numbers
- 003
US 7,304,036 with pediatric exclusivity, as listed
patent.txt lines 3,331, 3,347, 3,365- Expiry as listed
- 28 Feb 2027
- Rule
- R2
- Flags
- substance · product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002, 003
US 8,933,030, product and use patent
patent.txt line 3,342- Expiry as listed
- 17 Feb 2031
- Rule
- R1
- Flags
- product · use code U-4345
- Product numbers
- 001
US 8,933,030, product patent
patent.txt line 3,356- Expiry as listed
- 17 Feb 2031
- Rule
- R1
- Flags
- product
- Product numbers
- 002
US 8,933,030, product and use patent
patent.txt line 3,370- Expiry as listed
- 17 Feb 2031
- Rule
- R1
- Flags
- product · use code U-1516
- Product numbers
- 003
US 8,933,030, product and use patent
patent.txt line 3,371- Expiry as listed
- 17 Feb 2031
- Rule
- R1
- Flags
- product · use code U-3644
- Product numbers
- 003
US 8,933,030, product and use patent
patent.txt line 3,372- Expiry as listed
- 17 Feb 2031
- Rule
- R1
- Flags
- product · use code U-4566
- Product numbers
- 003
US 10,675,325, product patent
patent.txt line 3,360- Expiry as listed
- 11 Aug 2031
- Rule
- R1
- Flags
- product
- Product numbers
- 003
US 10,702,576, use patent
patent.txt line 3,362- Expiry as listed
- 11 Aug 2031
- Rule
- R1
- Flags
- use code U-1516
- Product numbers
- 003
US 10,702,576, use patent
patent.txt line 3,363- Expiry as listed
- 11 Aug 2031
- Rule
- R1
- Flags
- use code U-3644
- Product numbers
- 003
US 10,702,576, use patent
patent.txt line 3,364- Expiry as listed
- 11 Aug 2031
- Rule
- R1
- Flags
- use code U-4566
- Product numbers
- 003
US 8,933,030 with pediatric exclusivity, as listed
patent.txt lines 3,341, 3,355, 3,369- Expiry as listed
- 17 Aug 2031
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002, 003
US 8,748,573, use patent
patent.txt line 3,338- Expiry as listed
- 30 Oct 2031
- Rule
- R1
- Flags
- use code U-4345
- Product numbers
- 001
US 8,748,573, use patent
patent.txt lines 3,336, 3,351- Expiry as listed
- 30 Oct 2031
- Rule
- R1
- Flags
- use code U-1515
- Product numbers
- 001, 002
US 8,748,573, use patent
patent.txt lines 3,337, 3,352- Expiry as listed
- 30 Oct 2031
- Rule
- R1
- Flags
- use code U-1516
- Product numbers
- 001, 002
US 8,802,628, product patent
patent.txt lines 3,340, 3,354- Expiry as listed
- 30 Oct 2031
- Rule
- R1
- Flags
- product
- Product numbers
- 001, 002
US 10,675,325 with pediatric exclusivity, as listed
patent.txt line 3,359- Expiry as listed
- 11 Feb 2032
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 003
US 10,702,576 with pediatric exclusivity, as listed
patent.txt line 3,361- Expiry as listed
- 11 Feb 2032
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 003
US 8,748,573 with pediatric exclusivity, as listed
patent.txt lines 3,335, 3,350- Expiry as listed
- 30 Apr 2032
- Rule
- R2
- Flags
- pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 8,802,628 with pediatric exclusivity, as listed
patent.txt lines 3,339, 3,353- Expiry as listed
- 30 Apr 2032
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002
US 9,708,371, product and use patent
patent.txt line 3,346- Expiry as listed
- 16 Aug 2033
- Rule
- R1
- Flags
- product · use code U-4345
- Product numbers
- 001
US 9,708,371, product and use patent
patent.txt lines 3,344, 3,358- Expiry as listed
- 16 Aug 2033
- Rule
- R1
- Flags
- product · use code U-1515
- Product numbers
- 001, 002
US 9,708,371, product and use patent
patent.txt lines 3,345, 3,374- Expiry as listed
- 16 Aug 2033
- Rule
- R1
- Flags
- product · use code U-1516
- Product numbers
- 001, 003
US 9,708,371, product and use patent
patent.txt line 3,375- Expiry as listed
- 16 Aug 2033
- Rule
- R1
- Flags
- product · use code U-3644
- Product numbers
- 003
US 9,708,371, product and use patent
patent.txt line 3,376- Expiry as listed
- 16 Aug 2033
- Rule
- R1
- Flags
- product · use code U-4566
- Product numbers
- 003
US 9,708,371 with pediatric exclusivity, as listed
patent.txt lines 3,343, 3,357, 3,373- Expiry as listed
- 16 Feb 2034
- Rule
- R2
- Flags
- product · pediatric, as listed by FDA (from the base row)
- Product numbers
- 001, 002, 003
Listed exclusivities
Each exclusivity FDA lists for NDA 202811, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
I-921 exclusivity
exclusivity.txt lines 294, 297- Date
- 12 Jun 2026
- Rule
- R3
- Definition
- New indication (to be checked against FDA's list)
- Product numbers
- 001, 003
NPP exclusivity
exclusivity.txt line 295- Date
- 4 Nov 2028
- Rule
- R3
- Definition
- New patient population (to be checked against FDA's list)
- Product numbers
- 001
PED exclusivity
exclusivity.txt line 296- Date
- 4 May 2029
- Rule
- R3
- Definition
- Pediatric exclusivity (to be checked against FDA's list)
- Product numbers
- 001
NPP exclusivity
exclusivity.txt line 298- Date
- 21 May 2029
- Rule
- R3
- Definition
- New patient population (to be checked against FDA's list)
- Product numbers
- 003
Paragraph IV list rows giving NDA 202811
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 202811, each cell as listed.
FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.
The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.
Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.
Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 202811
Linaclotide · Capsules · 145 mcg and 290 mcg
RLD/NDA as listed: Linzess 202811- First PIV submission
- 30 Aug 2016
- ANDAs
- 4
- 180-day status
- Deferred
- Decision posted
- 22 Feb 2021
- First applicant approval
- 9 Feb 2021
- First marketing
- blank
- Last qualifying patent expiry (as listed by FDA)
- 30 Oct 2031
Linaclotide · Capsules · 72 mcg
RLD/NDA as listed: Linzess 202811- First PIV submission
- 7 Nov 2017
- ANDAs
- 1
- 180-day status
- Deferred
- Decision posted
- 28 Sep 2026
- First applicant approval
- 24 Sep 2026
- First marketing
- blank
- Last qualifying patent expiry (as listed by FDA)
- 16 Aug 2033
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week